Hello. I'm Fredrik Schjesvold a head of Oslo Myeloma Center in Norway. I'm here at the EHA 25 in Milano, Italy. I'm here to present the poster about the beam trial.
The beam trial is a real world, data set, gathered from European patients, 84 European patients and 184 American patients. U.S. patients receiving belantamab mafodotin in immunotherapy in, real world routine practice.
As you might know, belantamab was restricted from the market as immunotherapy. But it's coming back now. Being approved as a combination therapy.
With a showed the large benefit in combination pomalidomide or bortezomib, against daratumumab and against, bortezomib. So looking at the real world data for the monotherapy, there are some, important messages.
One thing is that we see the same PFS, progression free survival in this real world data as we do in, in the clinical studies, of course, that it's, these are extremely heavily approaching the patients in the US patients. Almost 30% had more than six months of therapy.
And, the majority of patients in both cohorts had more than 4 or 5 lines of therapies.
The PFS is around three, four months, which is like in the trial, but we see a much larger, PFS in the combination studies that are being improved now.
But this study wasn't, mainly about that. The study was mainly about the side effects, the ocular events we see as a problem.
So people get correctable here, which means that, you don't see good, blurred vision, for instance.
So what we saw that there were two different ways of doing this in the European and the US. In Europe, we only had the baseline and then examinations for first cycles, while in the US you had to use, go to ophthalmologist before each cycle.
So let's, follow up for that in Europe. I would say maybe the most important part of this, poster is to show that you don't need that extensive follow up.
You see, in the US, there was not more the not keratopathy, eye problems in the European cohorts with less extensive, optimal logical examinations, because this has been a hurdle for the for the drug that you need to see ophthalmologist all the time.
So what we're now going to do this in Europe and in my country is that we're going to have a baseline examination.
And then we just follow most a for symptoms. If there was no indication of, more follow up in the beginning.
And we also see, importantly in this trial that the dropout, the patients who stopped because of adverse events, because of these ocular, symptoms, it's very low is 7 to 8%.
So it means that most patients are able to stay on the drug, and just delay the dose or reduce the dose and still be able to use this.
And this is in real world practice. And it's good to see that we can sort of find the same results in there as we did in the clinical trials.
And let's also hope that that will be for the combination studies.
HealthTree • June 27, 2025